News in the Life Sciences Industry

STOCKHOLM, Sept. 18, 2019 /PRNewswire/ -- Biovica and the SWOG Cancer Research Network have entered into an agreement to study the clinical benefit of DiviTum® using patient blood samples from SWOG 0226, a clinical trial that showed that women with metastatic hormone receptor-positive breast... Read more ››

LINKÖPING, Sweden, Sept. 16, 2019 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra... Read more ››

STOCKHOLM, Sept. 15, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The... Read more ››

GOTHENBURG, Sweden, Sept. 12, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study (ISO-CC-007) in metastatic colorectal cancer... Read more ››

STOCKHOLM, Sept. 12, 2019 /PRNewswire/ -- During 15-17 September, RaySearch will exhibit its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2019 annual meeting in Chicago, USA. On show will be new development in machine learning technology and... Read more ››

STOCKHOLM, Sept. 12, 2019 /PRNewswire/ -- Karo Pharma Aktiebolag ("Karo Pharma") today announces that the acquisition of all the shares of Trimb Holding AB ("Trimb") from Avista Capital Partners and other shareholders for MSEK 3,400, which was signed on 21 June, 2019 and approved... Read more ››

SHENZHEN, China, Sept. 12, 2019 /PRNewswire/ -- Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, today launched the BeneHeart C Series automated external defibrillator (AED) with smarter operations and faster shock delivery to achieve better resuscitation... Read more ››

STOCKHOLM, Sept. 11, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results from the Phase 3 OPTIMUM study for ponesimod, an investigational selective S1P1 receptor modulator, showing superior efficacy on the primary endpoint and most secondary... Read more ››